Chiesi

Medical Information is a Chiesi function that answers enquiries from healthcare professionals and consumers about marketed products, as well as unapproved and pipeline products.

The company says rare diseases affect millions worldwide, and that patient journeys often involve uncertainty, late diagnoses, limited treatment options and complex care pathways.

Akiza Ndibanje Josh Mathis Qadesh was born in Burundi after a difficult delivery and suffered severe birth asphyxia. Doctors, nurses and midwives worked to stabilize him in the neonatal unit while his parents stayed at his side.

Chiesi scientists at the Paolo Chiesi R&D Campus in Parma are exploring whether a digital representation of the human lung could help study and predict how therapies may work for individual patients.

The Chiesi Group accelerates sustainable growth in the first half of 2025, delivering solid financial results and a commitment to creating shared value.

Chiesi Farmaceutici Spa’s media hub provides news, press releases and multimedia resources about the company’s advancements, collaborations and initiatives in healthcare.

The U.S. Food and Drug Administration approved Chiesi’s BDP/FF/G triple therapy in a single inhaler for maintenance treatment of asthma in adults. Two Phase 3 studies, TRIMARAN and TRIGGER, evaluated its safety and efficacy in more than 2,500 adults with uncontrolled asthma.

For all press and media inquiries, please contact mediarelations@chiesi.com.

The company fosters a collaborative culture where everyone can contribute their talents to innovate and create value.

Chiesi fosters a collaborative culture where people bring their talents together to drive innovation and create impact.

The company develops and markets therapeutic solutions for respiratory health and rare diseases.

Chiesi focuses its scientific activities on respiratory health, rare diseases and specialty care. It listens to patients, caregivers and healthcare professionals and integrates their insights into the development and availability of its solutions.

The company promotes a responsible approach to business in which business results and social progress go hand in hand.

The Chiesi Group is headquartered in Parma, Italy, and is supported by 31 subsidiaries worldwide. While maintaining strong Italian roots, it operates with a global vision and addresses the major health challenges internationally.

A global biopharmaceutical company that helps people live healthier lives

The company develops and markets therapeutic solutions for respiratory health, rare diseases and specialty care.

Pursuant to Article 13 of Regulation (EU) 2016/679 on the protection of individuals withregard to the processing of Personal Data (hereinafter ‘GDPR’).

B Lab licenses the “Certified B Corporation” designation to companies that complete its B Impact Assessment and meet its requirements for social and environmental performance, accountability and transparency.